Allarity Therapeutics, Inc.
ALLR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.04 | 0.00 | 0.00 |
| FCF Yield | -14.64% | -34.91% | -257.19% | -190.06% |
| EV / EBITDA | -2.54 | 0.32 | 8.56 | 2.21 |
| Quality | ||||
| ROIC | -20.96% | -30.52% | -15.16% | -55.60% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.22 | 2.36 | 0.98 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 37.79% | -104.06% | 23.34% | 35.62% |
| Safety | ||||
| Net Debt / EBITDA | 6.71 | 7.15 | 8.95 | 2.46 |
| Interest Coverage | 44.18 | -344.42 | -53.26 | -97.56 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -34,537.50 | -35,566.36 | 33,435.00 |